Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group

Table 1 Summary of Cost and Survival differences for selected CCTG trials

Trial	n	Survival \({E}_{1}\) (Years)		Cost \({C}_{1}\) (CAD)		\(\boldsymbol\rho\)
Trial	n	SE	\(\boldsymbol\sigma\)	SE	\(\boldsymbol\sigma\)	\(\boldsymbol\rho\)
BR.10	172	0.2930	2.717	3,757	34,840	0.124
BR.21	731	0.0325	0.622	558	10,668	0.203
LY.12^a	519	0.0045	0.073	1,807	29,103	0.042
CO.17 (all patients)	567	0.0184	0.309	958	16,130	0.44
CO.17 (KRAS subgroup)	226	0.0296	0.316	1,598	16,987	0.43

E₁ Experimental arm effectiveness, C₁ experimental arm cost, \(\rho\) Correlation Coefficient, SE Standard Error, \(\sigma\) Standard deviation, CAD Canadian Dollars
^a LY.12 is a non-inferiority design. For LY.12, survival is defined as the restricted mean QALY from randomization to stem cell mobilization

ISSN: 1471-2288